Niagen Bioscience Inc (NAGE) financials
Niagen Bioscience revenue and earnings by year
Niagen Bioscience's revenue was $129 million in the fiscal year to December 31, 2025, up 29.9% from the year before. Net income was $17.4 million, 13.4% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 22.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129 | 100 | 84 | 72 | 67 | 59 | 46 | 32 | 21 | 22 |
| Revenue growth | 29.9% | 19.2% | 16.0% | 6.8% | 13.8% | 28.0% | 46.7% | 48.8% | -2.1% | — |
| Gross profit | 83 | 62 | 51 | 43 | 41 | 35 | 26 | 16 | 10 | 10 |
| Gross margin | 64.3% | 61.8% | 60.8% | 59.4% | 61.5% | 59.5% | 55.7% | 50.9% | 49.4% | 48.0% |
| Operating income | 16 | 8 | -6 | -19 | -27 | -20 | -31 | -33 | -16 | -3 |
| Operating margin | 12.6% | 7.8% | -6.7% | -25.9% | -40.1% | -33.5% | -67.6% | -105.3% | -77.2% | -13.4% |
| Net income | 17 | 9 | -5 | -17 | -27 | -20 | -32 | -33 | -11 | -3 |
| Net margin | 13.4% | 8.6% | -5.9% | -23.0% | -40.2% | -33.6% | -69.4% | -105.6% | -53.7% | -13.5% |
| Diluted EPS | $0.20 | $0.11 | -$0.07 | -$0.24 | -$0.40 | -$0.33 | -$0.56 | -$0.61 | -$0.25 | -$0.08 |
| Free cash flow | 13 | 12 | 7 | -15 | -25 | -11 | -21 | -22 | -11 | -4 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open NAGE in Markets.
How Niagen Bioscience makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Consumer Products | $24.2M | 81.1% |
| Ingredients | $5.39M | 18.1% |
| Corporate & Reconciling Items | $236K | 0.8% |
See also: NAGE valuation and P/E history · NAGE returns
No forecast, no recommendation. This page describes Niagen Bioscience Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.